LNAI · CIK 0001527728 · operating
Lunai Bioworks Inc. is a pre-clinical stage biotechnology company developing immunotherapeutic and diagnostic products for oncology and biodefense applications. The company's primary focus is on genetically modified allogeneic dendritic cell therapeutic vaccines designed to treat solid tumors, with RENB-DC11 in development for pancreatic cancer and RENB-DC20 for breast cancer treatment. Additionally, Lunai operates an artificial intelligence platform technology intended for early cancer detection and recurrence monitoring that employs multi-omics analysis to identify individual biomarkers in asymptomatic patients.
The company operates through three segments: RENB, focused on the dendritic cell vaccine programs; BioSymetrics, supporting the AI-driven diagnostic platform; and RENC, which addresses biodefense products. All products remain in pre-clinical development stages with no approved medicines currently commercialized.
Lunai Bioworks maintains a small operational footprint with 29 full-time employees and is headquartered in Los Angeles, California, with operations extending to the Netherlands. The company was incorporated in Delaware and is listed on Nasdaq. It was formerly known as Renovaro Inc. prior to changing its name in August 2025.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-1.08 | $-1.08 | -28.6% | |
| 2024 | $-0.84 | $-0.84 | -18.3% | |
| 2023 | $-0.71 | $-0.71 | — | |
| 2022 | — | — | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2014 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-06-30 | 2025-09-29 | 0001731122-25-001316 | SEC ↗ |
| 2024-06-30 | 2024-10-10 | 0001731122-24-001578 | SEC ↗ |
| 2023-06-30 | 2023-10-02 | 0001731122-23-001770 | SEC ↗ |
| 2022-06-30 | 2023-02-27 | 0001731122-23-000271 | SEC ↗ |
| 2021-06-30 | 2021-09-24 | 0001731122-21-001565 | SEC ↗ |
| 2020-06-30 | 2020-09-23 | 0001731122-20-000975 | SEC ↗ |
| 2019-06-30 | 2019-09-30 | 0001731122-19-000575 | SEC ↗ |
| 2018-06-30 | 2018-10-01 | 0001731122-18-000094 | SEC ↗ |
| 2017-06-30 | 2017-09-29 | 0001213900-17-010130 | SEC ↗ |
| 2016-06-30 | 2016-09-28 | 0001213900-16-017105 | SEC ↗ |
| 2014-12-31 | 2015-03-31 | 0001213900-15-002253 | SEC ↗ |
| 2013-03-31 | 2013-07-16 | 0001213900-13-003650 | SEC ↗ |
| 2012-03-31 | 2012-07-17 | 0001213900-12-003853 | SEC ↗ |